CD8-depleted haploidentical donor T cells

CD8-depleted haploidentical donor T cells are an investigational adoptive cell therapy developed by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. This therapy involves the infusion of donor lymphocytes that have been laboratory-processed to deplete CD8+ cytotoxic T cells, thereby enriching for CD4+ helper T cells. These cells are obtained from a partially HLA-mismatched (haploidentical) donor. The treatment is typically administered following a lymphodepleting conditioning regimen, such as high-dose cyclophosphamide. The primary therapeutic goal is to induce a graft-versus-leukemia (GVL) effect, where the donor T cells recognize and eliminate residual malignant cells in patients with high-risk hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic myelomonocytic leukemia (CMML). The depletion of CD8+ cells is a strategy intended to reduce the risk and severity of graft-versus-host disease (GVHD) while maintaining the anti-tumor activity of the graft.

Other names

CD8-depleted donor lymphocytesCD-8-depleted donor lymphocytesCD 8-depleted donor lymphocytesCD8-depleted peripheral blood cellsCD-8-depleted peripheral blood cellsCD 8-depleted peripheral blood cellshaploidentical CD8-depleted T cellsDonor T cells-Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins-myelodysplastic syndrome-acute myeloid leukemia-chronic myelomonocytic leukemia